Who's Who Legal
Who's Who Legal
New to Who's Who Legal?
New to Who's Who Legal?
Menu
User Menu
New to Who's Who Legal?
Thought Leaders

Thought Leaders

Dieter Gericke

Dieter Gericke

HomburgerPrime TowerHardstrasse 201ZurichSwitzerlandCH-8005

Thought Leader

WWL Ranking: Thought Leader
WWL Ranking: Thought Leader

Global Leader

WWL Ranking: Recommended

WWL says

Dieter Gericke is highly sought after by clients who praise his “top-quality work” as well as his “very broad knowledge of corporate law and equity transactions”.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International by Givaudan, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries

In his areas of practice, Dieter Gericke authored various publications, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of directors of Syngenta, a leading agrotechnology group, and of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries.

Corporate Governance - 2019

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke has an impressive presence in the corporate governance field and broad experience covering shareholder activism matters and proxy fights, among other issues.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of specialty vaccines company PaxVax to Emergent BioSolutions, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the acquisition of Activ International by Givaudan, the sale of Infront Sports & Media to Dalian Wanda, the acquisition of Ulysse Nardin by Kering, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and legal opinions, including on global M&A, securities laws, directors' and officers' duties and liability and say-on-pay regulations. He is a member of the IBA corporate and M&A committee, and the securities law committee.

Dieter Gericke is a member of the board of directors of Syngenta, a leading agrotechnology group, and of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries.

Healthcare 2020

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke is praised as a "knowledgeable, business-oriented and fast" practitioner who finds "sustainable, practical and sound solutions".

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and is former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International by Givaudan, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

M&A 2019

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke is praised as "a great lawyer" with a notable practice that runs the gamut of corporate transactions, including reverse mergers and unsolicited takeovers.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of specialty vaccines company PaxVax to Emergent BioSolutions, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the acquisition of Activ International by Givaudan, the sale of Infront Sports & Media to Dalian Wanda, the acquisition of Ulysse Nardin by Kering, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and legal opinions, including on global M&A, securities laws, directors' and officers' duties and liability and say-on-pay regulations. He is a member of the IBA corporate and M&A committee, and the securities law committee.

Dieter Gericke is a member of the board of directors of Syngenta, a leading agrotechnology group, and of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries.

National Leader

Switzerland - Capital Markets

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke leads the firm’s corporate and M&A practice group, and is well respected in the market for his expertise in securities regulation and capital markets transactions.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of specialty vaccines company PaxVax to Emergent BioSolutions, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the acquisition of Activ International by Givaudan, the sale of Infront Sports & Media to Dalian Wanda, the acquisition of Ulysse Nardin by Kering, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and legal opinions, including on global M&A, securities laws, directors' and officers' duties and liability and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as securities law committee.

Dieter Gericke is a member of the board of directors of Syngenta, a leading agrotechnology group, and of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries.

WWL Ranking: Recommended

WWL says

Dieter Gericke wields over 18 years of experience in corporate governance law and securities regulation, an area in which he is recognised as a key figure in the Swiss market.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of specialty vaccines company PaxVax to Emergent BioSolutions, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the acquisition of Activ International by Givaudan, the sale of Infront Sports & Media to Dalian Wanda, the acquisition of Ulysse Nardin by Kering, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and legal opinions, including on global M&A, securities laws, directors' and officers' duties and liability and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as securities law committee.

Dieter Gericke is a member of the board of directors of Syngenta, a leading agrotechnology group, and of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries.

Switzerland - M&A

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke directs the firm’s corporate and M&A team. He is "certainly a good name" in the Swiss corporate market according to peers, who praise his outstanding work on complex M&A transactions.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of specialty vaccines company PaxVax to Emergent BioSolutions, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the acquisition of Activ International by Givaudan, the sale of Infront Sports & Media to Dalian Wanda, the acquisition of Ulysse Nardin by Kering, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and legal opinions, including on global M&A, securities laws, directors' and officers' duties and liability and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as securities law committee.

Dieter Gericke is a member of the board of directors of Syngenta, a leading agrotechnology group, and of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries.

Law Business Research
Law Business Research Ltd
Meridian House, 34-35 Farringdon Street
London EC4A 4HL, UK
© Law Business Research Ltd 1998-2019. All rights reserved.
Company No.: 03281866